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Mitochondrial impairment and increased oxidative stress are considered to be involved in the patho-
genesis of neurodegenerative diseases, such as Alzheimer's disease. Coenzyme Q10 (CoQ10) is a
component of the electron transport chain localized on the inner membrane of the mitochondria. In
addition to its bioenergetic activity required for ATP synthesis, CoQ10 also has antioxidant activity in
mitochondrial and lipid membranes, which protects against the reactive oxidative species generated
during oxidative phosphorylation. Several previous studies had reported no signiﬁcant differences in
serum CoQ10 levels between patients with and without dementia, such as Alzheimer's disease. However,
in this issue of Atherosclerosis, Yamagishi et al. demonstrate for the ﬁrst time that a lower serum CoQ10
level is associated with a greater risk of dementia in a Japanese general population. These ﬁndings
suggest that assessing serum CoQ10 levels could be useful for predicting the development of dementia,
rather than as a biomarker for the presence of dementia.
© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Mitochondria play an essential role in energy productionwithin
cells, and energy is generated through oxidative phosphorylation in
the form of adenosine triphosphate (ATP). Mitochondrial impair-
ment and increased oxidative stress are considered to be involved
in the pathogenesis of neurodegenerative diseases, such as Alz-
heimer's disease, which is the most common form of dementia in
the elderly [1,2]. Increased oxidative stress was shown to be present
in the brains of patients with Alzheimer's disease and to induce the
accumulation of amyloid-beta protein [3,4]. Of note, amyloid-beta
protein can impair mitochondrial function and induce oxidative
stress. Coenzyme Q10 (CoQ10), also known as ubiquinone, is a
component of the electron transport chain, which is located at the
inner membrane of the mitochondria and plays a major role in ATP
synthesis [5,6]. In addition to this bioenergetic activity required for
ATP synthesis, CoQ10 also has antioxidant activity in both mito-
chondrial and lipid membranes, which protects them against the
reactive oxidative species generated during oxidative phosphory-
lation. Several studies have already investigated the associations
between dementia, such as Alzheimer's disease, and serum CoQ10
or antioxidant levels [7e9]. However, in this issue of Atherosclerosis,
Yamagishi et al. [10] demonstrate for the ﬁrst time that a lower
level of serum CoQ10 and a lower ratio of CoQ10/total cholesterolatherosclerosis.2014.09.017.
This is an open access article undeare associated with a greater risk of disabling dementia in a general
population.
Regarding serum CoQ10 levels in patients with dementia, de
Bustos et al. [8] investigated serum CoQ10 levels in 44 patients with
Alzheimer's disease, 17 patients with vascular dementia and 21
controls. However, no signiﬁcant differences were found in CoQ10
levels among the 3 groups. Since CoQ10 levels correlate with total
cholesterol levels [11], the ratio of CoQ10/cholesterol was also
calculated. However, total cholesterol levels and the ratio of CoQ10/
cholesterol did not differ among the 3 groups. Moreover, a
population-based cross-sectional study by von Armin et al. [7]
measured serum CoQ levels, as well as antioxidants (vitamin C, E,
and beta-carotene) levels, in 74 mildly demented subjects and 158
controls. Vitamin C and beta-carotene levels were signiﬁcantly
lower in the demented subjects than in controls, but there were no
differences in CoQ10 and vitamin E levels between the 2 groups.
Giavarotti et al. [9] also investigated plasma oxidative stress bio-
markers, including CoQ10, in 23 patients with Alzheimer's disease
and 42 cognitively intact subjects. Vitamin E levels were lower in
patients with Alzheimer's disease, but there were no differences in
CoQ10, vitamin C or beta-carotene levels between the 2 groups.
Although Polidori et al. [12] reported that both vitamin C and E
levels were lower in 86 patients with dementia than in 55 controls,
the association between dementia and antioxidant levels, such as
vitamin C and E, is still controversial. Regarding Lewy body disease
which is the second most frequent cause of dementia in the elderly,r the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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18 patients with Lewy body disease than in 20 controls, but there
was no signiﬁcant difference in the CoQ10/cholesterol ratio be-
tween the 2 groups. Hence, the results of these previous studies
suggest that serum CoQ10 levels are unlikely to differ between
patients with and without the presence of dementia, such as Alz-
heimer's disease. However, as de Bustos et al. [8] and Soderberg
et al. [14] commented, normal serum CoQ10 levels cannot rule out
the possibility that there may be regional alterations of CoQ10 in
some areas of the brain.
In this issue of Atherosclerosis, Yamagishi et al. [10] report their
population-based prospective cohort study of approximately 6000
Japanese subjects aged 45e70 years at baseline (1984e1994) who
were followed for at least 5 years. CoQ10 levels at baseline were
measured in 65 subjects who developed disabling dementia with
dementia-related behavioral disturbance or cognitive impairment
during the follow-up compared with 130 age- and gender-matched
controls. They demonstrated an inverse association between serum
CoQ10 levels at baseline and the risk of incident disabling de-
mentia, independent of various risk factors. Moreover, they re-
ported that there was an inverse association between the ratio of
CoQ10/total cholesterol and the risk of dementia. These results
suggest that serum CoQ10 levels can be a predictor for dementia,
but not a biomarker for the presence of dementia, in a Japanese
general population. It should be kept in mind that it is currently
unclear whether these results can be generalized for other ethnic
populations. Moreover, as the authors commented, they did not
classify dementia into Alzheimer's disease and vascular dementia.
Instead, they reported that CoQ10 levels tended to bemore strongly
associated with dementia in subjects without a history of stroke
than in those with a history of stoke. However, because the number
of demented subjects was limited, further studies in a larger pop-
ulation are needed to conﬁrm the differences regarding CoQ10
levels between dementia with and without a history of stroke.
Several experimental studies have shown the neuroprotective
effects of CoQ10. Choi et al. [15] reported that CoQ10 protected
neurons against amyloid-beta-induced neurotoxicity, mainly by
inhibiting oxidative stress, in the rat cortex. Using transgenic mice
overexpressing amyloid protein presenilin-1, Yang et al. [16] also
showed treatment with CoQ10 to attenuate amyloid-beta over-
production and intracellular deposits associated with reduced
oxidative stress in the cortex. Moreover, Dumont et al. [17] showed
that CoQ10 treatment reduced oxidative stress and amyloid pa-
thology and then improved cognitive behavior in the Tg19959
mouse model of Alzheimer's disease. Using transgenic mice with
the P301S tau mutation, which causes fronto-temporal dementia,
Elipenahil et al. [18] also demonstrated that CoQ10 treatment
improved the survival and behavioral deﬁcits associated with up-
regulated mitochondrial enzymes and reduced oxidative stress.
Therefore, these ﬁndings suggest that CoQ10 plays a protective role
as an endogenous antioxidant against the development or pro-
gression of dementia, especially Alzheimer's disease. However, in
humans, a randomized clinical trial with 400 mg of CoQ10 three
times/day for 16 weeks in 78 patients with mild to moderate Alz-
heimer's disease did not show any signiﬁcant beneﬁcial effects on
cerebrospinal ﬂuid biomarkers for Alzheimer's disease, such asamyloid-beta and tau levels [19]. Therefore, as Yamagishi et al. [10]
commented in this issue of Atherosclerosis, CoQ10 may have a more
prominent impact on prevention, rather than on treatment, of de-
mentia, and serum CoQ10 levels may be a useful predictor of the
development of dementia, rather than a biomarker for the presence
of dementia. Both assessing serum CoQ10 levels and evaluating the
effects of CoQ10 treatment are worthy of further studies to deter-
mine the predictive values of serum CoQ10 levels with regard to the
development of dementia and to assess the preventative effects of
CoQ10 treatment in a larger population.References
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